Genomic Health, Inc. (NASDAQ:GHDX)
| CAPS Rating |
|
|---|---|
| Open | $26.49 |
| Previous Close | $26.59 |
| Daily Range | $25.90 - $27.00 |
| 52-Week Range | $19.00 - $29.52 |
| Market Cap | $793.93M |
| P/E Ratio | 97.40 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 324,061 |
| Average Daily Volume | 0 |
GHDX
VS S&P 500 (SPY)
How do you think GHDX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GHDX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GHDX News and Commentary
- Genomic Health Meets on Revenues, Misses on EPS – The Motley Fool
- Genomic Misses, Grows Annually - Analyst Blog – NASDAQ
- Myriad Beats, Raises Guidance - Analyst Blog – NASDAQ
- Genomic's Useful Colon Cancer Test - Analyst Blog – NASDAQ
- Myriad Gets Rights to RAD51C Gene - Analyst Blog – NASDAQ
- Amass a Fortune With These Stocks – The Motley Fool
- Genomic Looks to Diversify Offering (revised) - Analyst Blog – NASDAQ
- Genomic Looks to Diversify Offering - Analyst Blog – NASDAQ
- Myriad Reverts to Neutral - Analyst Blog – NASDAQ
- Ideas: 10 Stocks With Rising Gross Profit Margins and Insider Buying – The Motley Fool
- Myriad Bracanalysis Proves Cheaper - Analyst Blog – NASDAQ
- Genomic DCIS Score Coming Shortly - Analyst Blog – NASDAQ
- Genomic Health to Sell Test to Predict Breast Cancer Recurrence – Minyanville
- Genomic Health to Showcase Key Data - Analyst Blog – NASDAQ
- The 10 Most-Watched Diagnostic Substances Stocks – The Motley Fool
- Can the Human Genetics Industry Survive the Courts? – The Motley Fool
- A Quick Glance at the Stocks in David Swensen's Yale Portfolio – The Motley Fool
- A Simplified ASCO 2011 List for Biotech Investor Research – SeekingAlpha
- The GBMB in review, part III – Blog at The Motley Fool
- Why cancer diagnostics aren't simple. – Blog at The Motley Fool
RSS Headlines
Fool UK
